FDPS and osteoporosis: Zoledronic acid (ZA), a nitrogen-containing bisphosphonate, is currently recognized as the first-line pharmacologic treatment for osteoporosis, which can selectively suppress osteoclastic bone resorption through effectively inhibiting farnesyl pyrophosphate synthase (FPPS) activity in the mevalonate pathway (Black et al., 2007; Rogers et al., 2020).